Chemoradiotherapy responsiveness in Rectal Cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1075149

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and lead to a personalized treatment of rectal cancer.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2017

Funding Scheme: Postgraduate Scholarships

Funding Amount: $117,636.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Gene Expression (incl. Microarray and other genome-wide approaches)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biomarkers | cancer genetics | cancer therapy | colorectal cancer | radiation therapy

Related Links